Could Pfizer's true cost to acquire Icagen be as little as $22 million?
This article was originally published in Scrip
Executive Summary
Further details have become available concerning a letter from two institutional stockholders, Merlin Nexus and New Leaf Venture, to Icagen's board charging that Pfizer's offer for the remaining shares of its partner for $56 million undervalues Icagen's assets.